Clinical Trial

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

A Norwegian biotech has dosed its first patient with a novel TCR-NK therapy, a potential breakthrough in delivering scalable, precise treatment for solid tumors.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

A breakthrough study shows a wearable ear device can stimulate nerves to enhance the body’s natural clotting, offering a drug-free future for saving lives.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

New research reveals a popular brain training app may reduce key Alzheimer's biomarkers, offering a potential non-drug path to combat neurodegeneration.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

Clinical-stage Nyra Medical begins a key U.S. study for its novel mitral valve device, a strategic move challenging established players in a crowded field.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.